Amarin (AMRN) vs Lifecore Biomedical (LFCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Lifecore Biomedical (LFCR) has outperformed Amarin (AMRN) over the past year, losing 6.4% versus a loss of 37.8%. Over five years, LFCR leads with a -34.5% price change compared with -88.4% for AMRN. Amarin is the larger company by market cap ($254.1 million vs $244.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMRN | LFCR |
|---|---|---|
| Share price | $12.03 | $6.45 |
| Market cap | $254.11M | $244.49M |
| 1-day change | +0.33% | +0.31% |
| YTD return | -14.11% | -21.39% |
| 1-year return | -37.81% | -6.40% |
| 5-year return | -88.38% | -34.45% |
| Forward P/E | 12.28 | — |
| EPS (TTM) | $-1.20 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.90 | $8.98 |
| 52-week low | $11.83 | $3.63 |
| Distance from 52-week high | -42.44% | -28.17% |
| Analyst consensus | none | hold |
| Avg. price target upside | +3.91% | -2.64% |
| Average volume | 66.23K | 294.61K |
| Shares outstanding | 21.12M | 37.91M |
| Employees | 80 | 382 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LFCR has outperformed AMRN by 31.4 percentage points over the past year.
About Amarin
AMRN stock →Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees
About Lifecore Biomedical
LFCR stock →Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities.
Health Care · Biotechnology: Pharmaceutical Preparations · 382 employees
AMRN vs LFCR FAQ
Which is bigger, Amarin or Lifecore Biomedical?
Amarin (AMRN) is larger, with a market capitalization of $254.11M compared with $244.49M for Lifecore Biomedical (LFCR).
Which stock has performed better over the past year, AMRN or LFCR?
LFCR returned -6.40% over the past 12 months, compared with -37.81% for AMRN (price return, excluding dividends). Past performance does not predict future results.
Are Amarin and Lifecore Biomedical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.